Tidal Investments LLC Sells 6,712 Shares of Repligen Co. (NASDAQ:RGEN)

Tidal Investments LLC trimmed its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 60.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,437 shares of the biotechnology company's stock after selling 6,712 shares during the period. Tidal Investments LLC's holdings in Repligen were worth $639,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Oppenheimer & Co. Inc. acquired a new position in Repligen during the 4th quarter valued at about $216,000. Van ECK Associates Corp boosted its position in shares of Repligen by 7.8% during the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after buying an additional 3,066 shares during the period. Stephens Investment Management Group LLC grew its holdings in Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after buying an additional 37,057 shares in the last quarter. LPL Financial LLC increased its position in Repligen by 47.6% in the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock valued at $4,873,000 after acquiring an additional 10,395 shares during the period. Finally, Signaturefd LLC raised its stake in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Insider Activity

In other news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $4.66 during midday trading on Friday, reaching $117.66. The company's stock had a trading volume of 1,145,832 shares, compared to its average volume of 743,182. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a market capitalization of $6.61 billion, a P/E ratio of -230.71, a P/E/G ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business's fifty day simple moving average is $128.09 and its 200-day simple moving average is $143.65.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter in the prior year, the firm earned $0.28 earnings per share. The business's quarterly revenue was up 10.4% on a year-over-year basis. As a group, equities research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RGEN. HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Wall Street Zen upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target on the stock. Finally, Royal Bank of Canada decreased their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.